Terms: = Prostate cancer AND ERCC4, XPF, 2072, ENSG00000175595, Q92889
16 results:
1. A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh.
Babu G; Bin Islam S; Khan MA
Mol Biol Rep; 2022 Jul; 49(7):6725-6739. PubMed ID: 35277785
[TBL] [Abstract] [Full Text] [Related]
2. Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized prostate cancer.
Wallis CJD; Zhao Z; Huang LC; Penson DF; Koyama T; Kaplan SH; Greenfield S; Luckenbaugh AN; Klaassen Z; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Hoffman KE; Barocas DA
JAMA Oncol; 2022 Jan; 8(1):50-59. PubMed ID: 34792527
[TBL] [Abstract] [Full Text] [Related]
3. Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-xpf-mediated DNA repair.
Ciniero G; Elmenoufy AH; Gentile F; Weinfeld M; Deriu MA; West FG; Tuszynski JA; Dumontet C; Cros-Perrial E; Jordheim LP
Cancer Chemother Pharmacol; 2021 Feb; 87(2):259-267. PubMed ID: 33399940
[TBL] [Abstract] [Full Text] [Related]
4. Variation in adjuvant and early salvage radiotherapy after robot-assisted radical prostatectomy for prostate cancer: a population-based cohort study.
Draulans C; Van Damme N; Isebaert S; Everaerts W; Silversmit G; Joniau S; De Meerleer G; Van Eycken E; Haustermans K;
Acta Oncol; 2020 Aug; 59(8):904-910. PubMed ID: 32723224
[No Abstract] [Full Text] [Related]
5. Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer.
Schroeder C; Grell J; Hube-Magg C; Kluth M; Lang D; Simon R; Höflmayer D; Minner S; Burandt E; Clauditz TS; Büscheck F; Jacobsen F; Huland H; Graefen M; Schlomm T; Sauter G; Steurer S
BMC Cancer; 2019 Mar; 19(1):193. PubMed ID: 30823906
[TBL] [Abstract] [Full Text] [Related]
6. Polymorphisms in nucleotide excision repair genes and risk of primary prostate cancer in Chinese Han populations.
Wang M; Li Q; Gu C; Zhu Y; Yang Y; Wang J; Jin L; He J; Ye D; Wei Q
Oncotarget; 2017 Apr; 8(15):24362-24371. PubMed ID: 27974699
[TBL] [Abstract] [Full Text] [Related]
7. Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study.
Terada N; Akamatsu S; Okada Y; Negoro H; Kobayashi T; Yamasaki T; Matsui Y; Inoue T; Kamba T; Ogawa O
Int J Clin Oncol; 2016 Dec; 21(6):1155-1161. PubMed ID: 27351872
[TBL] [Abstract] [Full Text] [Related]
8. Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study.
Agalliu I; Kwon EM; Salinas CA; Koopmeiners JS; Ostrander EA; Stanford JL
Cancer Causes Control; 2010 Feb; 21(2):289-300. PubMed ID: 19902366
[TBL] [Abstract] [Full Text] [Related]
9. NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans.
Hooker S; Bonilla C; Akereyeni F; Ahaghotu C; Kittles RA
Prostate Cancer Prostatic Dis; 2008; 11(4):349-56. PubMed ID: 18026184
[TBL] [Abstract] [Full Text] [Related]
10. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.
Cummings M; Higginbottom K; McGurk CJ; Wong OG; Köberle B; Oliver RT; Masters JR
Biochem Pharmacol; 2006 Jul; 72(2):166-75. PubMed ID: 16756962
[TBL] [Abstract] [Full Text] [Related]
11. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer.
Damaraju S; Murray D; Dufour J; Carandang D; Myrehaug S; Fallone G; Field C; Greiner R; Hanson J; Cass CE; Parliament M
Clin Cancer Res; 2006 Apr; 12(8):2545-54. PubMed ID: 16638864
[TBL] [Abstract] [Full Text] [Related]
12. Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma: XPC polymorphisms modify smoking-related risk.
Huang WY; Berndt SI; Kang D; Chatterjee N; Chanock SJ; Yeager M; Welch R; Bresalier RS; Weissfeld JL; Hayes RB
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):306-11. PubMed ID: 16492920
[TBL] [Abstract] [Full Text] [Related]
13. Regulation of DNA repair gene expression in human cancer cell lines.
McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
[TBL] [Abstract] [Full Text] [Related]
14. Reduced levels of XPA, ERCC1 and xpf DNA repair proteins in testis tumor cell lines.
Welsh C; Day R; McGurk C; Masters JR; Wood RD; Köberle B
Int J Cancer; 2004 Jun; 110(3):352-61. PubMed ID: 15095299
[TBL] [Abstract] [Full Text] [Related]
15. Polymorphisms in DNA repair genes and associations with cancer risk.
Goode EL; Ulrich CM; Potter JD
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1513-30. PubMed ID: 12496039
[TBL] [Abstract] [Full Text] [Related]
16. Coordinated expression of matrilysin during TPA-induced apoptosis of LNCaP cells: two parallel processes affected by TPA.
Sundareshan P; Koster JJ; Nagle RB; Bowden GT
Cancer Lett; 1997 Feb; 113(1-2):17-24. PubMed ID: 9065796
[TBL] [Abstract] [Full Text] [Related]
